104 results about "Pathogenic Escherichia coli" patented technology

The invention relates to the technical field of microorganisms, in particular to animal-derived pediococcus acidilactici and application thereof. The pediococcus acidilactici is classified and named as pediococcus acidilactici, the strain number of the pediococcus acidilactici is 12NN1, the pediococcus acidilactici is preserved in Guangdong Microbial Culture Collection Center on January 2, 2025, and the preservation number of the pediococcus acidilactici is GDMCC No: 65706. The strain is resistant to acid and cholate, has a remarkable inhibiting effect on growth and reproduction of pathogenic escherichia coli and staphylococcus aureus, is safe and non-toxic, does not have pathogenicity, and provides beneficial strain resources and biological materials for development of corresponding microbial preparations. Therefore, the compound can be used for preparing a biocontrol preparation for inhibiting the growth of pathogenic bacteria, preparing animal feed and preparing a preparation for preventing, improving and / or treating gastrointestinal tract pathogenic bacteria infection, so that the compound has a wide application prospect.

The invention discloses lactobacillus reuteri with antioxidant, anti-inflammatory and anti-hypoxia capabilities, the name of the lactobacillus reuteri is QM11, the classification name of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation date of the lactobacillus reuteri is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing on August 5, 2024, and the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, and the preservation number of the lactobacillus reuteri is CGMCC NO.31541. The preservation unit is China General Microbiological Culture Collection Center (CGMCC). The lactobacillus reuteri is separated from faeces of healthy yaks in Qinghai province, has relatively strong acid and cholate tolerance, has relatively good antioxidant and anti-inflammatory capacities, and has a relatively strong inhibition effect on pathogenic bacteria such as yak-derived pathogenic escherichia coli, staphylococcus aureus and salmonella typhimurium; the sodium dextran sulfate induced mouse colitis symptom is relieved, and the hypoxia tolerance of the mouse is improved. The lactobacillus reuteri disclosed by the invention can be used for preparing medicines or microecological preparations for resisting oxidation, inflammation and hypoxia, and has a very wide application prospect.

The invention provides a nano preparation for breaking oxidative stress-inflammation vicious circle and regulating intestinal flora as well as a preparation method and application of the nano preparation. The preparation method of the preparation comprises the following steps: dissolving potassium ferricyanide and polyvinylpyrrolidone in a solution, slowly dropwise adding a zinc acetate dihydrate solution into the solution, stirring, standing, and repeatedly performing ultrafiltration centrifugal washing to obtain zinc-doped Prussian blue; crushing the yeast cells to obtain yeast cell walls; the yeast cell wall and the zinc-doped Prussian blue are repeatedly co-extruded through a liposome extruder to obtain the nano preparation. The ZnPBA in the nano material can efficiently remove active oxygen at an inflammation part and reduce secretion of inflammatory factors, and the oxidative stress-inflammatory vicious circle of ulcerative colitis is broken; meanwhile, the YCW can deliver the ZnPBA to an inflammation part in a targeted manner to kill pathogenic escherichia coli, and mannose components can promote growth of probiotics to realize bidirectional regulation of intestinal flora. The material is simple in preparation method, can be synthesized on a large scale and is used for treating ulcerative colitis.

Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).

The invention relates to a diarrhea-related multi-drug-resistant coliphage and application thereof. In particular to a bacteriophage vBEcoMP66 screened from a multi-drug-resistant escherichia coli library, and the bacteriophage vBEcoMP66 is preserved in the China Center for Type Culture Collection on December 12, 2024, and the preservation number is CCTCC M 20242794. The bacillus subtilis has a splitting effect on multiple strains of multi-drug-resistant escherichia coli and piglet diarrhea pathogenic escherichia coli strains, and also has an obvious inhibition effect on bacteria in a biological membrane, and the inhibition capability is superior to the antibiotic level under the same condition. Besides, the bacteriophage has extremely low host resistance mutation frequency, the resistance mutation frequency of host bacteria can be effectively reduced, animal experiments show that the bacteriophage has the effects of preventing piglet diarrhea and reducing the level of inflammatory factors in vivo, and the bacteriophage has extremely high industrial value and wide application prospects.

The present disclosure provides compositions and methods for making and using Salmonella recombinant bacteria that express LPS O78 antigen and / or virulence factors of avian pathogenic Escherichia coli (APEC) as vaccines to prevent colibacillosis infections.

The invention discloses a kit for simultaneously detecting 16 food-borne pathogenic bacteria. Each group of probes is designed based on bacterial classification, virulence gene specificity or serotype marks of the pathogenic bacteria; a group A probe vibrio detection group is used for detecting vibrio cholerae universal type, vibrio cholerae O1 serotype, vibrio cholerae O139 serotype and vibrio parahaemolyticus; the B group of probe invasive enterobacteriaceae pathogen group is used for detecting escherichia coli O157: H7, shigella, salmonella and yersinia small intestine; the C group probe escherichia coli pathotype detection group is used for detecting enterotoxigenic escherichia coli ETEC, enteroinvasive escherichia coli EIEC, enteroaggregative adherent escherichia coli EAEC and pathogenic escherichia coli EPEC; and the D group of probes are used for detecting campylobacter jejuni, campylobacter colons, listeria monocytogenes and enterohemorrhagic escherichia coli EHEC in the campylobacter and toxin type pathogen group.

The invention discloses a high-strength nano-composite antibacterial fabric which comprises a base fabric and a modified and sol-gel nano layer, the modified and sol-gel nano layer and the base fabric are compounded and smeared to form the nano-composite antibacterial fabric, and the modified and sol-gel nano layer is coated with the modified and sol-gel nano layer to form the high-strength nano-composite antibacterial fabric. The modified sol-gel nano layer comprises titanium dioxide sol, nano zinc oxide and a silver antibacterial agent, the base layer fabric is prepared from the following raw materials in percentage by weight: 10% of chitin fiber, 50% of Coolplus fiber, 40% of cotton fiber and 16.7 tex of yarn linear density, and the base layer fabric is prepared from the following raw materials in percentage by weight: 10% of chitosan fiber, 50% of Coolplus fiber, 40% of cotton fiber and 16.7 tex of yarn linear density. Compared with the prior art, the fabric has the advantages that a layer of uniform and firm porous nano antibacterial film is formed on the surface of the fabric, so that staphylococcus aureus and pathogenic escherichia coli can be effectively killed; the double-layer fabric formed by combining the chitin fibers, the Coolplus fibers and the cotton fibers has good antibacterial, bacteriostatic, rapid moisture absorption and moisture conduction functions.

The invention discloses a preparation method and application of a hexavalent multi-epitope fusion protein of avian pathogenic Escherichia coli. The invention preferably selects antigenic epitopes of the curli fimbriae subunit CsgA, lipoprotein SlyB, maltose porin LamB, outer membrane protein PhoE, proteolytic enzyme activator NlpD and lipoprotein Pal main structural subunit of avian pathogenic Escherichia coli, and preferably connects with the heat-labile enterotoxin LTb fusion protein in series to construct an antigenic multi-epitope fusion protein of six proteins of avian pathogenic Escherichia coli. The antigenic multi-epitope fusion protein has a wide serotype coverage, is non-allergenic, has strong immunogenicity, and produces strong specific humoral immunity and cellular immune response after immunizing animals.

A method for preparing a bacteriophage targeting extra-intestinal pathogenic Escherichia coli (ExPEC) comprising mixing pig (porcine) extraintestinal E. coli host cells at logarithmic phase with phage

The invention provides a product for detecting eight food-borne pathogenic bacteria by time-of-flight mass spectrometry, which comprises a specific primer group of multiple PCR (Polymerase Chain Reaction) of the eight food-borne pathogenic bacteria, wherein the food-borne pathogenic bacteria comprise intestinal aggregation Escherichia coli, intestinal hemorrhagic Escherichia coli, intestinal invasive Escherichia coli, intestinal pathogenic Escherichia coli, Shiga toxin producing Escherichia coli, enterotoxin producing Escherichia coli, listeria monocytogenes and salmonella typhimurium. The detection vehicle product is used for carrying out multiple PCR amplification on pathogen DNA, and the size of a fragment of the multiple PCR product is detected through MALDI-TOF MS (matrix-assisted laser desorption / ionization time of flight mass spectrometry). According to the method, multiple PCR and MALDI-TOF MS are combined to be used for identifying clinical pathogenic microorganisms, and the method is rapid, simple, convenient, easy to observe, visual and high in accuracy.

The invention relates to the technical field of microorganisms, in particular to duck-origin functional bacillus and application thereof. According to the invention, two new probiotic strains are separated from intestinal contents and excrement of ducks, the two strains are identified as bacillus sp., the two strains are respectively named as bacillus TWF01 (Bacillus sp.TWF01) and bacillus TWF02 (Bacillus sp.TWF02), and the preservation numbers of the two strains are respectively CCTCC (China Center for Type Culture Collection) NO: M2024942 and CCTCC NO: M2024943. The duck-origin functional bacillus disclosed by the invention is a specific potential functional probiotic capable of inhibiting the growth of pathogenic escherichia coli, the formation of a biological membrane and the expression of a virulence gene.

The invention discloses a traditional Chinese medicine composition for preventing and treating avian pathogenic escherichia coli as well as a preparation method and application thereof, and relates to the technical field of veterinary drugs. According to the invention, screening is carried out through subtraction genomics and reverse network pharmacology, and based on the compatibility theory of monarch, minister, assistant and guide and the traditional Chinese veterinary medicine and pharmacy differentiation theory, a traditional Chinese medicine composition, namely the radix angelicae and fructus forsythiae intestine health formula, for preventing and treating avian pathogenic escherichia coli is formed. According to the traditional Chinese medicine composition, fructus forsythiae and radix angelicae are used as monarch drugs, radix isatidis and clinopodium polycephalum are used as ministerial drugs, fructus aurantii immaturus, mint and plantain herb are used as adjuvant drugs, and liquorice is used as a conductant drug, so that the traditional Chinese medicine composition can inhibit reproduction of avian pathogenic escherichia coli, destroy formation of biological membranes of the avian pathogenic escherichia coli and relieve pathological injuries of diseased poultry caused by APEC; the traditional Chinese medicine composition has a good treatment effect on avian pathogenic escherichia coli.

The invention relates to the technical field of microorganisms, in particular to an escherichia coli bacteriophage for improving the antibacterial effect of cecropin and application of the escherichia coli bacteriophage. The bacteriophage is named as RDP-EC-22139, the genome of the bacteriophage does not contain virulence genes and lyogenicity related genes, and the bacteriophage has good biological safety. The bacteriophage has relatively strong lysis activity on drug-resistant pathogenic escherichia coli, can still keep stable lysis titer in a relatively wide temperature and pH condition range, and has good genetic stability. When the bacteriophage is combined with cecropin for use, the minimum inhibitory concentration of the cecropin on drug-resistant pathogenic escherichia coli is remarkably reduced, the minimum inhibitory concentration can be reduced to 1 / 2-1 / 8 of the minimum inhibitory concentration when the cecropin is independently used, the inhibition time on pathogenic bacteria is remarkably prolonged, and a stable and unexpected synergistic antibacterial effect is shown. The invention provides a safe and effective biological technical scheme for prevention and control of drug-resistant Escherichia coli infection, and has a good application prospect.

The invention discloses a bacteriophage capable of splitting pathogenic escherichia coli and application of the bacteriophage. The phage is named as Escherichia coli phage vBEcoMYS1, and is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number of the phage is GDMCC No: 67465-B1vBEcoMYS1. Experiments prove that the bacteriophage has relatively strong splitting capacity, relatively strong thermal stability and relatively strong pH stability, and can keep high titer under the conditions that the temperature is 4-40 DEG C and the pH is 5-9. The bacteriophage can be used for splitting multiple escherichia coli, including enterotoxigenic escherichia coli (ETEC) and shiga toxin-producing escherichia coli (STEC), has a relatively wide splitting spectrum, and can be used as an antibiotic substitute. In addition, the genome of the bacteriophage does not contain virulence genes and antibiotic resistance genes, so that the bacteriophage has good biological safety.

The invention relates to the technical field of molecular biomedicine, in particular to a method for identifying enteropathogenic Escherichia coli, which comprises the following steps: screening virulence genes, determining a Cutom Markers gene, detecting mNGS of a clinical specimen, comparing off-machine data and identifying the enteropathogenic Escherichia coli. The specificity of the identification method reaches 99.9%, and the sensitivity reaches 96.8% when the detection sequence of escherichia coli is greater than or equal to 10k reads. By utilizing the method, the accuracy and applicability of enteropathogenic escherichia coli identification can be remarkably improved, and the method can be widely applied to the field of clinical microbiological detection.

The application belongs to the technical field of bioengineering, and particularly relates to a bacteriophage PE-2 of Escherichia coli with high blood entry efficiency and fermentation efficiency and application. The bacteriophage involved in the application has a preservation number of CCTCC NO: M20252973, and can specifically lyse pathogenic Escherichia coli O2 serotype and has high blood entry efficiency. The bacteriophage can enter blood circulation through oral administration, and can be widely distributed to the spleen, liver, heart and other tissues through blood circulation. The bacteriophage can be prepared in pilot production to obtain a very high titer, and the titer reaches 1.6x10 12 PFU / mL. Compared with the production of antibiotics, the production cost of the bacteriophage is low, and the bacteriophage provides a source and a reference example for industrial production of high-titer bacteriophage.

The present invention provides an adhesion-enhanced engineered probiotic and its application, wherein the bacterium contains a recombinant plasmid pBbB8K‑LFCA‑FaeG‑FaeC. The engineered probiotic has a strong adhesion to intestinal epithelial cells, and competitively inhibits the adhesion of pathogenic Escherichia coli K88 to intestinal epithelial cells. The engineered probiotic of the present invention is a non-antibiotic Escherichia coli, which is more environmentally friendly and avoids antibiotic tolerance for animals. Immunizing animals with it has a better immune effect, can activate dendritic cells in Peyer's patches and mesenteric lymph nodes, promote T cell and B cell immune responses, maintain the integrity of the intestinal barrier to resist pathogen infection and improve intestinal inflammation, improve the abundance of intestinal probiotics, and reduce the abundance of pathogenic bacteria. The adhesion-enhanced probiotic prepared by the present invention can significantly inhibit bacterial enteritis in mice, providing an effective treatment for inflammatory bowel disease and other gastrointestinal diseases.

The invention belongs to the field of food, and relates to a new application of myricetin-3-O-galactoside. The invention provides an application of myricetin-3-O-galactoside in preparation of a food for improving urinary tract infection. The invention also provides a food for improving urinary tract infection, and the food comprises myricetin-3-O-galactoside. The myricetin-3-O-galactoside is proved to have the effect of inhibiting the adhesion activity of urinary tract pathogenic escherichia coli for the first time, and the myricetin-3-O-galactoside can be used as an adhesion inhibiting active agent for urinary tract infection pathogen urinary tract pathogenic escherichia coli and can be used for preparing food for effectively improving urinary tract infection.

The invention provides a kit for detecting multiple piglet diarrhea pathogens and a detection method, and belongs to the technical field of biological information detection. The kit comprises a reaction reagent, wherein the reaction reagent comprises a porcine epidemic diarrhea virus specific primer and a probe, a porcine delta coronavirus specific primer and a probe, a piglet pathogenic escherichia coli specific primer and a probe, a clostridium perfringens specific primer and a probe, a buffer solution, an enzyme mixed solution and a freeze-drying protective additive. The detection method adopts the kit for detecting various piglet diarrhea pathogens. According to the kit disclosed by the invention, simultaneous detection of four target genes including the porcine epidemic diarrhea virus, the porcine delta coronavirus, the piglet pathogenic escherichia coli and the clostridium perfringens can be realized only through one-time amplification, so that the detection time is greatly shortened while the detection cost is reduced; the kit has extremely high specificity, sensitivity and repeatability, and the primers and the probes do not interfere with each other; good normal-temperature storage stability is also realized.

The invention discloses a strain of leuconostoc mesenteroides V7, and the microbial preservation number is CGMCC (China General Microbiological Culture Collection Center) No.34824. The leuconostoc mesenteroides V7 disclosed by the invention is applied to products for inhibiting source avian pathogenic escherichia coli. The leuconostoc mesenteroides V7 disclosed by the invention has an inhibition effect on avian pathogenic escherichia coli, so that the leuconostoc mesenteroides V7 can be used for replacing antibiotics in poultry production and breeding to treat avian pathogenic colibacillosis. The invention provides a novel antibiotic substitute, which can obviously improve the infection condition of avian pathogenic escherichia coli in poultry bodies and avoid the problems of antibiotic abuse and bacterial drug resistance as much as possible.

The application discloses a dog-derived Enterococcus faecalis ZJUIDS-D016 with anti-aging effect and application, the dog-derived Enterococcus faecalis ZJUIDS-D016 is classified and named as (Enterococcus faecalis) Enterococcus faecalis ), and the preservation number is CGMCC 27038.The strain of the application is isolated from the intestinal tract of a healthy dog, has acid resistance, bile salt resistance and broad-spectrum antibacterial activity, and is sensitive to chloramphenicol, erythromycin and penicillin.The strain of the application has strong host adaptability, can colonize in the intestinal tract of a dog and secrete organic acids and bacteriocins, significantly inhibits the proliferation of common pathogenic bacteria such as dog pathogenic escherichia coli, effectively improves the intestinal health of pets and delays aging, and is suitable for preparing pet probiotic products.

The invention relates to a strain of virulent Escherichia coli bacteriophage PYYF4 and a culture method thereof, a bacteriophage composition, a feed additive, a sterilization and disinfection preparation and application, and belongs to the technical field of microorganisms. The virulent escherichia coli bacteriophage PYYF4 disclosed by the invention can be used for effectively preventing and / or treating infection caused by pathogenic escherichia coli and can be used for disinfecting environments and instruments. Moreover, the strong escherichia coli bacteriophage PYYF4 disclosed by the invention has a high splitting rate and a broad-spectrum bactericidal effect, keeps stable in the pH range of 4-11 and the temperature range of 40-60 DEG C, and shows good environmental adaptability. Meanwhile, the virulent escherichia coli bacteriophage PYYF4 is free of toxic and side effects, high in safety, easy to prepare into spraying liquid, convenient for practical application and wide in application prospect in the aspects of escherichia coli infection prevention and treatment, environment disinfection and animal disease treatment.

The present invention discloses a non-pathogenic Escherichia coli isolate expressing only F4 fimbriae adhesin and its application. The growth rate of the strain of the present invention is similar to that of the standard reference strain C83902 of F4ac+ enterotoxigenic Escherichia coli, and it exhibits good adhesion to the small intestinal epithelial cells of piglets in vitro experiments. Immunizing mice with the fimbriae adhesin extract extracted from the isolate or immunizing piglets with the inactivated vaccine prepared based on the isolate can induce the production of high-titer anti-FaeG antibodies, and the obtained immune piglet serum significantly inhibits the adhesion of the F4ac+ETEC domestic reference strain C83902 strain to IPEC‑J2 cells. The non-pathogenic Escherichia coli isolate is expected to become a candidate live vaccine strain for preventing diarrhea in piglets caused by infection with enterotoxigenic Escherichia coli expressing F4 fimbriae adhesin.

The invention discloses a method for preparing dephenolized cottonseed protein antibacterial peptide through an enzyme method, and belongs to the technical field of cottonseed protein antibacterial peptide preparation. According to the invention, cottonseed protein is used as a raw material, a composite hydrolase system is used for hydrolyzing the cottonseed protein under a certain condition, and the hydrolysate is purified through two-stage membrane separation, affinity chromatography and HPLC (High Performance Liquid Chromatography), so that the cottonseed protein antibacterial peptide with relatively strong antibacterial activity is finally obtained. The cottonseed protein antibacterial peptide is high in practicability, and the obtained cottonseed protein antibacterial peptide is high in antibacterial property, is a broad-spectrum antibacterial peptide, can inhibit negative bacteria including pathogenic escherichia coli and gram-positive bacteria, is a functional antibacterial peptide and has a good application prospect. The method can be widely applied to the fields of medicine, food, agriculture and the like, a feasible solution is provided for replacing traditional antibiotics, and remarkable economic and environmental benefits are achieved for promoting high-value utilization of cottonseed protein and reducing resource waste.

The invention relates to the technical field of escherichia coli biofilm formation determination, in particular to a method for determining the escherichia coli biofilm formation capacity through a crystal violet staining method. The method comprises the steps of bacterial liquid preparation, microwell plate sterilization, inoculation and culture, washing and fixation, dyeing and dissolution and quantitative detection. The method comprises the following steps: systematically analyzing biological characteristics such as biofilm forming ability, drug resistance, drug resistance genes and virulence genes of avian pathogenic escherichia coli through a multi-dimensional evaluation system, introducing a local isolated strain in Gansu province as a contrast, screening a strong biofilm forming strain in combination with ANOVA, and detecting the virulence genes through PCR (Polymerase Chain Reaction). The invention finds that the drug resistance rate of beta-lactams in a strong biofilm strain is as high as 82.3%, target data is provided for regional antibiotic control, meanwhile, a biofilm strength-virulence gene-drug resistance spectrum correlation model is established, the limitation of single phenotypic research is broken through, and the clinical treatment guidance value is improved.

The application discloses a protein molecule and application thereof in identifying avian pathogenic Escherichia coli of multiple serotypes, relates to the biological field, and the amino acid sequence of the protein molecule is shown as SEQ ID No:1. The protein molecule can specifically recognize avian pathogenic Escherichia coli of O2, O18 and O78 antigen serotypes, can be used for identifying avian pathogenic Escherichia coli of O2, O18 and O78 antigen serotypes, has the advantages of simplicity, rapidness, accuracy and the like, and has high application value.

The invention discloses a bacterial infection and LPS induced broiler chicken liver injury model and a construction method and application thereof, and the construction method comprises the following steps: administering 10-day-old broiler chicken with Escherichia coli E.coli O78 with a preset concentration in an intragastric administration manner; after broiler chickens are subjected to intragastric administration of escherichia coli for 18 hours, an LPS solution is injected into the intraperitoneal cavity of the broiler chickens, after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained, when the broiler chickens are 11 days old, the broiler chickens subjected to intragastric administration of escherichia coli are subjected to intraperitoneal injection of the LPS solution, and after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained. The broiler chicken liver injury model is constructed by intragastric administration of avian pathogenic escherichia coli (E.coli O78) and intraperitoneal injection of LPS (2 mg / kg), the pathology of the model is highly consistent with that of clinical broiler chicken bacterial liver injury, the liver has clinical typical lesions macroscopically, liver cells are degenerative and necrotic microscopically, and a molecular pathway activation mode is consistent with that of clinical application; the model constructed by the invention realizes specific liver injury, only the liver has specific injury, multiple organ lesions such as heart, peritoneum and the like do not exist, and the model availability is high.

The present disclosure relates to a composition for use in reducing the risk of an infection of the gastrointestinal tract caused by a pathogenic E. coli in a human subject, said composition comprising an effective amount of 2´-fucosyllactose, 3-fucosyllactose, 3'-sialyllactose, 6´-sialyllactose, and lacto-N-tetraose.